Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.

Mizuno S, Farkas L, Al Husseini A, Farkas D, Gomez-Arroyo J, Kraskauskas D, Nicolls MR, Cool CD, Bogaard HJ, Voelkel NF.

Am J Respir Cell Mol Biol. 2012 Nov;47(5):679-87. doi: 10.1165/rcmb.2012-0077OC. Epub 2012 Jul 27.

2.

Thyroid hormone is highly permissive in angioproliferative pulmonary hypertension in rats.

Al Husseini A, Bagnato G, Farkas L, Gomez-Arroyo J, Farkas D, Mizuno S, Kraskauskas D, Abbate A, Van Tassel B, Voelkel NF, Bogaard HJ.

Eur Respir J. 2013 Jan;41(1):104-14. doi: 10.1183/09031936.00196511. Epub 2012 Jul 26.

3.

VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics.

Lund AW, Duraes FV, Hirosue S, Raghavan VR, Nembrini C, Thomas SN, Issa A, Hugues S, Swartz MA.

Cell Rep. 2012 Mar 29;1(3):191-9. doi: 10.1016/j.celrep.2012.01.005. Epub 2012 Feb 23.

4.

Regulatory T cells and pulmonary hypertension.

Tamosiuniene R, Nicolls MR.

Trends Cardiovasc Med. 2011 Aug;21(6):166-71. doi: 10.1016/j.tcm.2012.05.004. Review.

5.

Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ, Nicolls MR.

Eur Respir J. 2012 Dec;40(6):1555-65. doi: 10.1183/09031936.00046612. Epub 2012 Jun 27. Review.

6.

Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms.

Finley SD, Popel AS.

AAPS J. 2012 Sep;14(3):500-9. doi: 10.1208/s12248-012-9363-4. Epub 2012 May 1.

7.

Bevacizumab and breast cancer: what does the future hold?

Stevenson CE, Nagahashi M, Ramachandran S, Yamada A, Bear HD, Takabe K.

Future Oncol. 2012 Apr;8(4):403-14. doi: 10.2217/fon.12.22. Review.

8.

Pulmonary arterial hypertension in patients treated by dasatinib.

Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, Poubeau P, Girerd B, Natali D, Guignabert C, Perros F, O'Callaghan DS, Jaïs X, Tubert-Bitter P, Zalcman G, Sitbon O, Simonneau G, Humbert M.

Circulation. 2012 May 1;125(17):2128-37. doi: 10.1161/CIRCULATIONAHA.111.079921. Epub 2012 Mar 26.

9.

Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling.

Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F, Casanovas O, Duarte A, Pytowski B, Adams RH.

Nature. 2012 Mar 18;484(7392):110-4. doi: 10.1038/nature10908.

PMID:
22426001
10.

Role of shear-stress-induced VEGF expression in endothelial cell survival.

dela Paz NG, Walshe TE, Leach LL, Saint-Geniez M, D'Amore PA.

J Cell Sci. 2012 Feb 15;125(Pt 4):831-43. doi: 10.1242/jcs.084301. Epub 2012 Mar 7.

11.

Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.

Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG, Wicha MS.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2784-9. doi: 10.1073/pnas.1018866109. Epub 2012 Jan 23.

12.

A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Gomez-Arroyo J, Saleem SJ, Mizuno S, Syed AA, Bogaard HJ, Abbate A, Taraseviciene-Stewart L, Sung Y, Kraskauskas D, Farkas D, Conrad DH, Nicolls MR, Voelkel NF.

Am J Physiol Lung Cell Mol Physiol. 2012 May 15;302(10):L977-91. doi: 10.1152/ajplung.00362.2011. Epub 2012 Feb 3. Review.

13.

Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans.

Bogaard HJ, Mizuno S, Guignabert C, Al Hussaini AA, Farkas D, Ruiter G, Kraskauskas D, Fadel E, Allegood JC, Humbert M, Vonk Noordegraaf A, Spiegel S, Farkas L, Voelkel NF.

Am J Respir Cell Mol Biol. 2012 May;46(5):582-91. doi: 10.1165/rcmb.2011-0296OC. Epub 2011 Dec 28.

14.

VEGFR2 translocates to the nucleus to regulate its own transcription.

Domingues I, Rino J, Demmers JA, de Lanerolle P, Santos SC.

PLoS One. 2011;6(9):e25668. doi: 10.1371/journal.pone.0025668. Epub 2011 Sep 28.

15.

The monocrotaline model of pulmonary hypertension in perspective.

Gomez-Arroyo JG, Farkas L, Alhussaini AA, Farkas D, Kraskauskas D, Voelkel NF, Bogaard HJ.

Am J Physiol Lung Cell Mol Physiol. 2012 Feb 15;302(4):L363-9. doi: 10.1152/ajplung.00212.2011. Epub 2011 Sep 30. Review.

16.

Altered MicroRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8.

Drake KM, Zygmunt D, Mavrakis L, Harbor P, Wang L, Comhair SA, Erzurum SC, Aldred MA.

Am J Respir Crit Care Med. 2011 Dec 15;184(12):1400-8. doi: 10.1164/rccm.201106-1130OC. Epub 2011 Sep 15.

17.

Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension.

Tamosiuniene R, Tian W, Dhillon G, Wang L, Sung YK, Gera L, Patterson AJ, Agrawal R, Rabinovitch M, Ambler K, Long CS, Voelkel NF, Nicolls MR.

Circ Res. 2011 Sep 30;109(8):867-79. doi: 10.1161/CIRCRESAHA.110.236927. Epub 2011 Aug 25.

18.

Design and validation of an endothelial progenitor cell capture chip and its application in patients with pulmonary arterial hypertension.

Hansmann G, Plouffe BD, Hatch A, von Gise A, Sallmon H, Zamanian RT, Murthy SK.

J Mol Med (Berl). 2011 Oct;89(10):971-83. doi: 10.1007/s00109-011-0779-6. Epub 2011 Jul 7.

19.

Molecular signature of a right heart failure program in chronic severe pulmonary hypertension.

Drake JI, Bogaard HJ, Mizuno S, Clifton B, Xie B, Gao Y, Dumur CI, Fawcett P, Voelkel NF, Natarajan R.

Am J Respir Cell Mol Biol. 2011 Dec;45(6):1239-47. doi: 10.1165/rcmb.2010-0412OC. Epub 2011 Jun 30.

20.

Inhibitory effects of SU5416, a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, on experimental corneal neovascularization.

Keskin U, Totan Y, Karadağ R, Erdurmuş M, Aydın B.

Ophthalmic Res. 2012;47(1):13-8. doi: 10.1159/000324994. Epub 2011 Jun 21.

PMID:
21691137

Supplemental Content

Support Center